SANUWAVE Health Inc. Common Stock (SNWV)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at SANUWAVE as a tiny medical-device turnaround, not a franchise. It sells noninvasive ultrasound and shockwave devices for tissue repair, with only 55 employees and a $48.3M market value at the 2026-10-13 close of $5.61. The filed record shows real improvement: revenue rose from $32.3M in fiscal year 2024 (period ended 2024-12-31) to $44.1M in fiscal year 2025 (period ended 2025-12-31), and net income swung from a $33.1M loss to $11.8M profit, with diluted EPS of $0.41. FairStock labels it a TURNAROUND for returning to profit after a loss in the last three years. But the latest filed quarters are weak: in fiscal Q1 2026 (quarter ended 2026-03-31), revenue was $9.6M and net loss was $1.4M, or diluted EPS -$0.17; in fiscal Q2 2026 (quarter ended 2026-06-30), revenue was $9.7M and net loss was $682,000, or diluted EPS -$0.08. Financial health is mixed. FairStock's Piotroski F-Score is 6/9, but Altman Z-Score is -8.10, and Graham Number is $1.31, leaving a -328.24% margin of safety at the close. P/B is 17.53, so book value offers little support. On the other side, free cash flow is $4.0M, FCF yield 8.3%, EV/EBITDA 3.05, PEG 0.31, and P/E 23.38. If earnings normalize, the price could be fair or cheap; if losses persist, it is expensive. The business shows no durable moat: it is small, has few employees, and lacks demonstrated pricing power. I would watch revenue growth, loss reduction, and cash flow durability.

In plain English: SANUWAVE Health makes medical devices that use ultrasound or shockwaves to help tissue heal. The business has grown from large losses to a profit in fiscal 2025, but it lost money again in the first half of fiscal 2026. At $5.61, the stock looks expensive compared with the company's net assets and latest losses, although some cash-flow and earnings-based measures look more reasonable.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer